J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Overall, this suggests that the cumulative risk of breast cancer before age 55 for women taking estrogen/progestin is about 4 ...

Hot flashes are a menopausal hallmark: Up to 80 percent of women have them. But numerous lesser-known symptoms are also ...

A new study led by researchers at Penn State College of Medicine suggests that long-term use of estrogen-based hormone ...